Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Kwon-Chung, Kyung J , Nguyen, M Hong , Palavecino, Elizabeth , Pancholi, Preeti , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Roilides, Emmanuel , Wengenack, Nancy L , Wiederhold, Nathan , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Luethy, Paul , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Gräser, Yvonne , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Leal, Sixto M. , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Wiederhold, Nathan P. , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | March 5, 2024 | Volume: 62 | Issue: 4 | Pages: No page available

10.1128/jcm.01625-23 | PMID 38441056 Get It

Analysis of editor in chief gender and associated journal variables among 126 pathology journals
Wang, Dayle K. , Clark, Landon M. , Adkins, Brian D. , Khan, Shazia S , Booth, Garrett S. , Jacobs, Jeremy W. , Adkins, Brian David , Booth, Garrett , Jacobs, Jeremy W , Stephens, Laura D.

Mayo Clinic

American Journal of Clinical Pathology | March 4, 2024 | Volume: 162 | Issue: 1 | Pages: 12-16

10.1093/ajcp/aqae018 | PMID 38437878 Get It

Abstract Objectives Gender equity studies have shown that women are underrepresented in journal editor in chief positions, which confer major professional opportunities and influence. We sought to systematically investigate editor in chief gender and journal attributes within pathology. Methods We constructed a journal data set using the Scimago Journal & Country Rank and Clarivate Journal Citation Reports databases. We also included official journals of the major medical societies for the 12 pathology subspecialties recognized by the Association of American Medical Colleges. The final data set included 126 journals. We obtained editor in chief gender, impact factor, publication model (ie, hybrid access vs open access), year of founding, and geographic location for all included pathology journals. Results Women made up only 18% of the 141 total editor in chief positions. This inequity was present irrespective of all pathology journal variables studied. Among 10 journals with 2 editor in chief positions, 5 had only men and 5 had 1 man and 1 woman. All 3 journals with 3 editor in chief positions had 2 men and 1 woman. Conclusions Women are significantly underrepresented among editor in chiefs across pathology journals. Journals and affiliated members should advocate for diversity among these influential positions, given their impact on research, science, and medicine.
Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019
Renedo, Daniela , Aravkin, Aleksandr Y. , Bärnighausen, Till , Basu, Sanjay , Burkart, Katrin , Coberly, Kaleb, Criqui, Michael H. , Elgendy, Islam Y. , Gad, Mohamed M. , Hafezi‐Nejad, Nima , Kalani, Rizwan , Krishnamoorthy, Vijay , Lo, Warren , Miller, Ted R. , Misganaw, Awoke, Murray, Christopher J L , Natto, Zuhair S. , Ram, Pradhum , Roth, Gregory A. , Seylani, Allen, Shah, Nilay S. , Sharma, Purva, Song, Suhang , Wang, Cong , Xiao, Hong , Zand, Ramin , Falcone, Guido J. , Elgendy, Islam Y , Zand, Ramin , Acosta, Julián , Leasure, Audrey C. , Sharma, Richa , Krumholz, Harlan M. , Havenon, Adam de , Alahdab, Fares , Aryan, Zahra , Dai, Xiaochen , Desai, Rupak , Dharmaratne, Samath Dhamminda , Doshi, Rajkumar , Feigin, Valery L. , Filip, Irina , Ghozy, Sherief , Karaye, Ibraheem M. , Kısa, Adnan , Meštrović, Tomislav , Mokdad, Ali H. , Radfar, Amir , Sheikh, Aziz , Singh, Jasvinder A. , Sotoudeh, Houman , Vervoort, Dominique , Xu, Suowen , Sheth, Kevin N.

Mayo Clinic

JAMA Neurology | March 4, 2024 | Volume: 81 | Issue: 4 | Pages: 394

10.1001/jamaneurol.2024.0190 | PMID 38436973 Get It

ImportanceStroke is a leading cause of death and disability in the US. Accurate and updated measures of stroke burden are needed to guide public health policies.ObjectiveTo present burden estimates of ischemic and hemorrhagic stroke in the US in 2019 and describe trends from 1990 to 2019 by age, sex, and geographic location.Design, Setting, and ParticipantsAn in-depth cross-sectional analysis of the 2019 Global Burden of Disease study was conducted. The setting included the time period of 1990 to 2019 in the US. The study encompassed estimates for various types of strokes, including all strokes, ischemic strokes, intracerebral hemorrhages (ICHs), and subarachnoid hemorrhages (SAHs). The 2019 Global Burden of Disease results were released on October 20, 2020.ExposuresIn this study, no particular exposure was specifically targeted.Main Outcomes and MeasuresThe primary focus of this analysis centered on both overall and age-standardized estimates, stroke incidence, prevalence, mortality, and DALYs per 100 000 individuals.ResultsIn 2019, the US recorded 7.09 million prevalent strokes (4.07 million women [57.4%]; 3.02 million men [42.6%]), with 5.87 million being ischemic strokes (82.7%). Prevalence also included 0.66 million ICHs and 0.85 million SAHs. Although the absolute numbers of stroke cases, mortality, and DALYs surged from 1990 to 2019, the age-standardized rates either declined or remained steady. Notably, hemorrhagic strokes manifested a substantial increase, especially in mortality, compared with ischemic strokes (incidence of ischemic stroke increased by 13% [95% uncertainty interval (UI), 14.2%-11.9%]; incidence of ICH increased by 39.8% [95% UI, 38.9%-39.7%]; incidence of SAH increased by 50.9% [95% UI, 49.2%-52.6%]). The downturn in stroke mortality plateaued in the recent decade. There was a discernible heterogeneity in stroke burden trends, with older adults (50-74 years) experiencing a decrease in incidence in coastal areas (decreases up to 3.9% in Vermont), in contrast to an uptick observed in younger demographics (15-49 years) in the South and Midwest US (with increases up to 8.4% in Minnesota).Conclusions and RelevanceIn this cross-sectional study, the declining age-standardized stroke rates over the past 3 decades suggest progress in managing stroke-related outcomes. However, the increasing absolute burden of stroke, coupled with a notable rise in hemorrhagic stroke, suggests an evolving and substantial public health challenge in the US. Moreover, the significant disparities in stroke burden trends across different age groups and geographic locations underscore the necessity for region- and demography-specific interventions and policies to effectively mitigate the multifaceted and escalating burden of stroke in the country.
“It’s Pink!”
Block, Darci R , Chandrasekar, Aswath P. , Block, Darci R , Wang, Qian

Mayo Clinic

Clinical Chemistry | March 2, 2024 | Volume: 70 | Issue: 3 | Pages: 565-566

10.1093/clinchem/hvad226 | PMID 38431274 Get It

A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis
Watkins, Ryan , Gamo, Ana M. , Choi, Seung Hyuk , Kumar, Manoj , Buckarma, EeeLN H. , McCabe, Chantal E. , Tomlinson, Jennifer L. , Pereya, David, Lupše, Blaž , Geravandi, Shirin , Werneburg, Nathan W., Zhu, Siying , Li, Sijia, Yu, Shan , Surakattula, Murali, Baguley, Tyler D., Ardestani, Amin , Roland, Jason, Petrassi, Mike, Rogers, Nikki Lynn, Chatterjee, Arnab K. , Tremblay, Matthew S. , Smoot, Rory L. , Buckarma, EeeLN , McCabe, Chantal , Tomlinson, Jennifer , Wang, Chen , Starlinger, Patrick , Li, Sijia , Ardestani, Amin , Maedler, Kathrin , Joseph, Sean , Rogers, Nikki , Gores, Gregory J. , Chatterjee, Arnab , Shen, Weijun , Smoot, Rory L , Wang, Chen , Starlinger, Patrick , Nguyen-Tran, Vân T. B. , Gores, Gregory J.

Mayo Clinic

PNAS Nexus | March 1, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgae096 | PMID 38528952 Get It

Abstract Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied. Utilizing a clinically approved small molecule inhibitor as a parent compound, standard medicinal chemistry approaches were utilized to generate a small molecule inhibitor targeting serine/threonine kinase 4/3 (MST1/2) with reduced off-target effects. This compound, mCLC846, was then applied to preclinical models of murine partial hepatectomy, which included models of diet-induced metabolic dysfunction-associated steatohepatitis (MASH). mCLC846 demonstrated on target inhibition of MST1/2 and reduced epidermal growth factor receptor inhibition. The inhibitory effects resulted in restored pancreatic beta-cell function and survival under diabetogenic conditions. Liver-specific cell-line exposure resulted in Yes-associated protein activation. Oral delivery of mCLC846 perioperatively resulted in accelerated murine liver regeneration and improved survival in diet-induced MASH models. Bulk transcriptional analysis of regenerating liver remnants suggested that mCLC846 enhanced the normal regenerative pathways and induced them following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided a survival benefit in models of diet-induced MASH.
Large Defect Involving the Central Cutaneous and Mucosal Upper Lip
Wang, Katherine , Degesys, Catherine A. , Barbosa, Naiara S. , Wang, Katherine L

Mayo Clinic

Dermatologic Surgery | February 28, 2024 | Volume: 50 | Issue: 11 | Pages: 1065-1067

10.1097/dss.0000000000004136 | PMID 38416812 Get It

Performance of CT With Adrenal-Washout Protocol in Heterogeneous Adrenal Nodules: A Multiinstitutional Study
Corwin, Michael T. , Caoili, Elaine M. , Elsayes, Khaled M. , Garratt, Joanie , Hackett, Caitlin E. , Mohd, Zahid, Sharbidre, Kedar , Yalon, Mariana , Navin, Patrick J. , Hudson, Emma, Mohd, Zahid, Shehata, Mostafa , Wang, Mindy X. , Wilson, Machelle , Remer, Erick M.

Mayo Clinic

American Journal of Roentgenology | February 28, 2024 | Volume: 222 | Issue: 5 | Pages: No page available

10.2214/ajr.23.30769 | PMID 38415578 Get It

Identification of immune cell markers associated with ulcerative colitis histological disease activity in colonic biopsies
Lefèvre, Pavine, Wang, Zhongya , Teft, Wendy A., Viegen, Tanja van, Linggi, Bryan, Jairath, Vipul , Feagan, Brian G. , Pai, Rish K. , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Casteele, Niels Vande

Mayo Clinic

Journal of Clinical Pathology | February 28, 2024 | Volume: 78 | Issue: 9 | Pages: 605-613

10.1136/jcp-2023-209327 | PMID 38418201 Get It

Aims Accurate determination of histological activity in ulcerative colitis (UC) is essential given its diagnostic and prognostic importance. Data on the relationship between histology and immune cell markers are limited. We aimed to evaluate the association between histological disease activity and immune cell marker concentration in colonic biopsies from patients with UC. Methods Sigmoid colon biopsies from 20 patients with UC were retrospectively assessed using the Robarts Histopathology Index (RHI). Targeted mass spectrometry determined the concentration of 18 immune cell markers (cluster of differentiation (CD) 4, CD8, CD19, CD20, CD40, CD56, CD68, CD103, forkhead box p3 (FOXP3), human leucocyte antigen, DR alpha chain (HLA-DRA), interleukin 10 (IL-10), IL-23 subunit alpha (IL-23A), IL-23 receptor (IL-23R), IL-2 receptor alpha chain (IL-2RA), Ki67, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD-1) and PD ligand 1 (PD-L1)). The association between RHI score and immune cell marker concentration was quantified using Spearman’s rank correlation coefficient (ρ) and related 95% CIs. Results Fourteen of the 18 immune cell marker proteins were detected, with tissue concentration ranging from 0.003 to 11.53 fmol/µg. The overall RHI score was positively correlated with CD19, CD20, CD40, FOXP3, LAG-3, PD-1 and PD-L1 concentration (ρ=0.596–0.799) and negatively correlated with CD56 concentration (ρ=−0.460). There was no significant association between RHI score and CD4, CD8, CD68, CD103, HLA-DRA or Ki67 concentration. Conclusions This study provides insight into the correlation between immune cell marker expression and histological disease activity and the possible molecular and immunological determinants underlying microscopic disease activity in UC.
A simple and effective genotyping workflow for rapid detection of CRISPR genome editing
Wang, Lingxiang, Wang, Jiale , Feng, Dongfeng , Jahan‐mihan, Yasmin , Bi, Yan , Lim, DoYoung, Ji, Baoan , Jahan-mihan, Yasmin, Bi, Yan , Ji, Baoan , Wang, Jiale , Wang, Bin , Wang, Ying

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | February 27, 2024 | Volume: 326 | Issue: 4 | Pages: G473-G481

10.1152/ajpgi.00013.2024 | PMID 38410866 Get It

This study presents a streamlined, cost-effective genotyping workflow for clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) edited mouse models, focusing on trypsinogen genes. It simplifies initial F0 mouse screening using PCR and Sanger sequencing without needing exact sequences. For F1 mice, precise editing is identified through Sanger sequencing and algorithm decoding. The workflow includes a novel PCR strategy for distinguishing homozygous and heterozygous statuses in subsequent generations, effective for small deletions, multiple-gene knockouts, and knockins.
Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma
Truong, Huong L. , Barreto, Jason N. , Mara, Kristin C. , Hampel, Paul J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Thanarajasingam, Gita , Thompson, Carrie A. , Wang, Yucai , Witzig, Thomas E. , Witzig, T.E. , Herrmann, Sandra M , Leung, Nelson , Wang, Yucai , Mara, Kristin C , Micallef, Ivana N , Herrmann, Sandra M. , Leung, Nelson

Mayo Clinic

JCO Oncology Practice | February 26, 2024 | Volume: 20 | Issue: 6 | Pages: 797-807

10.1200/op.23.00628 | PMID 38408299 Get It

PURPOSE Limited evidence exists regarding methotrexate (MTX) resumption after patients with lymphoma receive glucarpidase for toxic MTX levels and acute kidney injury (AKI). METHODS This retrospective review included adults with lymphoma treated with glucarpidase after MTX at Mayo Clinic between January 31, 2020, and October 10, 2022. Descriptive statistics summarize patient characteristics and clinical outcomes. RESULTS Of 11 patients treated with glucarpidase after MTX, seven (64%) were rechallenged with MTX. Indications for MTX rechallenge included confirmed CNS disease (n = 6, 86%) and intravascular lymphoma (n = 1, 14%). Compared with the nonrechallenged subgroup, before receiving MTX that required glucarpidase rescue, the rechallenged patients had lower median pretreatment serum creatinine (Scr; 0.7 v 1.2 mg/dL), and none had AKI with previous MTX doses, n = 0 (0%) versus n = 2 (50%). During the MTX dose requiring glucarpidase rescue, the rechallenged group had lower median peak Scr (1.26 v 3.32 mg/dL) and lower incidence of AKI stage III (n = 1 [14%] v n = 3 [75%]), and none of the rechallenged patients required renal replacement therapy (RRT; n = 0 [0%] v n = 1 [25%]). At the first rechallenge after glucarpidase administration, the median MTX dose reduction was 56% (range, 46%-75%), and the lowest used dose when prescribed according to each treatment protocol schedule was 1.5 g/m2. Two (29%) patients experienced AKI (n = 1 stage I, n = 1 stage II) after MTX rechallenge. Zero patients required RRT, and zero required another glucarpidase administration. Six (86%) patients completed all recommended MTX doses. CONCLUSION In selected adults with lymphoma who required glucarpidase for toxic MTX levels after administration of high-dose MTX, resumption of MTX therapy at lower doses is safe. Patients selected for MTX resumption had experienced less severe AKI during the previous cycle compared with those not selected for MTX resumption.